Patient Specific Factors
Patient Specific Factors - Related Videos
01:29
Factors Affecting Protein-Drug Binding: Patient-Related Factors
0 Views •
2025
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects. Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
11:33
Monitoring the Assembly of a Secreted Bacterial Virulence Factor Using Site-specific Crosslinking
0 Views •
Cited by 2 •
2013
This article illustrates the use of pulse-chase radio labeling in combination with site-specific photocrosslinking to monitor interactions between a protein of interest and other factors in E. coli. Unlike traditional chemical cross-linking methods, this approach generates high resolution “snapshots” of an ordered assembly pathway in a living cell.
12:09
Patient-specific Modeling of the Heart: Estimation of Ventricular Fiber Orientations
0 Views •
Cited by 14 •
2013
A methodology to estimate ventricular fiber orientations from in vivo images of patient heart geometries for personalized modeling is described. Validation of the methodology performed using normal and failing canine hearts demonstrate that that there are no significant differences between estimated and acquired fiber orientations at a clinically observable level.
07:30
3D Printing Model of a Patient's Specific Lumbar Vertebra
0 Views •
Cited by 4 •
2023
This study aims to create a 3D-printed model of a patient-specific lumbar vertebra, which contains both the vertebra and spinal nerve models fused from high-resolution computed tomography (HRCT) and MRI-Dixon data.
11:48
Patient-Specific Electric Field Simulation In Spinal Metastasis Electrochemotherapy
0 Views •
2026
This protocol describes a complete, reproducible workflow for patient-specific electric-field simulation and validation of electrochemotherapy (ECT) for spinal metastasis. The workflow integrates multimodal imaging, semi-automatic and manual segmentation, tissue conductivity modeling, linear finite-element electric-field simulation, and experimental validation via post-procedure MRI-based necrosis overlap analysis.
FAQs
Age and genetics can change both pharmacokinetics, how the body handles a medicine, and pharmacodynamics, how the medicine affects the body. These differences may alter exposure, response, and treatment tolerance even when patients receive the same regimen. Considering them alongside clinical findings helps clinicians interpret variable responses and select care plans better matched to the individual.
Comorbidities, organ function, and concurrent medications can modify the safety and effectiveness of treatment. They may influence how a therapy is processed, how strongly it acts, or whether adverse effects become more likely. Reviewing these factors before choosing a dose supports risk assessment and reduces dependence on a standardized regimen that may not fit the patient's clinical circumstances.
Patient-specific factors also affect how disease presents and how diagnostic findings should be understood. Age, genetics, comorbid conditions, lifestyle, and current medicines can shape the clinical picture, so the same finding may carry different significance across patients. Incorporating this context strengthens differential diagnosis and reduces the risk of basing decisions on isolated results alone.
A practical assessment begins by gathering information about age, genetics, comorbidities, organ function, medications, lifestyle, and preferences. Clinicians then relate these findings to disease risk, diagnostic possibilities, treatment options, and likely tolerance. This structured review turns patient history into actionable considerations for risk assessment, dose selection, and personalized treatment planning.
Assessment does not end when treatment starts. Patient-specific information should continue to guide monitoring because response and tolerance may require the care plan to be revisited. Tracking relevant clinical changes helps clinicians evaluate effectiveness, recognize adverse events, and adjust management when the original choice or dose no longer suits the patient's circumstances.
In clinical research, accounting for patient-specific factors helps make findings more representative of the people who will receive care. These characteristics can explain differences in treatment response and tolerance across participants, while their systematic assessment supports precision medicine. The resulting evidence can better inform individualized treatment planning rather than assuming one protocol performs equally for everyone.